UW AID faculty, fellows and medical team have been at the front lines of the COVID-19 pandemic since the first case was reported in Seattle, leading in patient care and research activities. The UW Medicine Incident Response Medical Team is led by Dr. John Lynch, Medical Director of Harborview Medical Center’s Infection Prevention and Control. More than 90 documents on policies and protocols in response to the outbreak were developed by the infection prevention team, including Drs. Chloe Bryson-Cahn, Santiago Neme and Seth Cohen, assisted by many other faculty and staff in the Division of Allergy and Infectious Diseases as well as others. These documents have been posted on an outward facing website and widely adapted across the nation and internationally.
The UW Vaccine Trials and Evaluation Unit (VTEU) was one of the sites for the NIAID clinical trial of remdesivir. The UW PI for the trial was Dr. Helen Chu, as part of a team including Drs. Maggie Green, Elizabeth Duke, Amanda Casto, and Anna Wald. Remdesivir, an antiviral drug that was originally tested against Ebola, has been shown to improve clinical outcomes against the new coronavirus, SARS-CoV-2, as reported by the National Institutes of Health. Preliminary results from this study showed that patients who received remdesivir recovered at a faster rate than those who did not take the drug.